<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4BB2A21C-D14F-4668-97EE-D7E122D74D22"><gtr:id>4BB2A21C-D14F-4668-97EE-D7E122D74D22</gtr:id><gtr:firstName>Marika</gtr:firstName><gtr:surname>Kullberg</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700806"><gtr:id>0ABC6608-1E0D-4491-8C9F-E5325F424BAF</gtr:id><gtr:title>Helicobacter-induced CD4+ Th17 responses in intestinal inflammation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700806</gtr:grantReference><gtr:abstractText>Inflammatory bowel disease (IBD), including Crohn?s disease and ulcerative colitis, is a significant health concern worldwide. In the United Kingdom alone there are ~150,000 people affected and 9,000 new cases diagnosed each year. With no cure existing, available treatments (medications, nutritional therapies, and surgery) are aimed at dampening the inflammation in the gut, thereby reducing the symptoms for the individual. However, there are many patients for whom these therapies are not effective, making the development of new therapeutic treatments a main priority and necessity.

The cause of IBD is not known; however, the intestinal bacterial flora is believed to be one factor contributing to the onset of disease in patients with these illnesses. A group of white blood cells called T helper (Th) lymphocytes that are part of the body?s immune system are believed, for unknown reasons, to ?attack? bacteria in the gut leading to intestinal inflammation. Recent data from both experimental models and human genetic studies has revealed that a protein called interleukin-23 (IL-23) plays an important role in the development of intestinal inflammation. It is currently unclear how IL-23 contributes to chronic inflammation; however, evidence suggests that this protein is essential for the expansion of a particular type of Th lymphocytes called Th17 cells. Th17 cells are believed to contribute to tissue pathology in certain autoimmune diseases through their production of the cytokines IL-17 and IL-22. To date, very little is known about the role of Th17 cells in intestinal inflammation. Thus, further research in this area will help our understanding of the process by which bacteria induce pathology in the gut, information that will be of utmost importance for the design of new therapeutic intervention strategies for IBD. 

In this project, we will use an experimental model of intestinal inflammation involving infection with the bacterium Helicobacter hepaticus to study Th17 cells in intestinal pathology. In particular, we will examine how these cells develop and survive in the gut, and also characterize their production of cytokines such as IL-17 and IL-22 at different time points following infection. Moreover, we will use various novel in vivo approaches to block the action of Th17 cells or the cytokines they secrete to elucidate their role in the inflammatory process. Together, our studies will provide important information concerning harmful immune responses to intestinal bacteria that will help in the design of strategies towards the treatment of IBD in humans.</gtr:abstractText><gtr:technicalSummary>Inflammatory bowel disease (IBD), including Crohn?s disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract that is caused in part by a dysregulated immune response to the intestinal bacterial flora. Using experimental models and human genetic studies, recent evidence from our group and others has demonstrated an important role for IL-23 and IL-23R signaling in the development of colitis. Although the precise mechanism by which IL-23 contributes to intestinal inflammation is unknown, reports over the past year have demonstrated that this cytokine is involved in the expansion of a novel CD4+ T cell subset termed Th17. These CD4+ T lymphocytes are characterized by their production of IL-17A, IL-17F, and IL-22, and have been implicated in disease pathogenesis in experimental autoimmune encephalomyelitis, another inflammatory disorder that is dependent on IL-23. Data from our Helicobacter hepaticus colitis model demonstrate increased production of T cell-derived IL-17A in mice with intestinal inflammation, opening up the possibility that the Th17 subset is involved in disease pathogenesis also in the intestinal tract. In this project, we will use our recently described model of intestinal inflammation involving anti-IL-10R treatment of H. hepaticus-infected WT mice to define the mechanisms underlying the IL-23 dependence of bacterial-induced T cell-dependent colitis. In particular, we will focus on Th17 cells and on experimental in vivo approaches where access to novel reagents will give us a competitive advantage in the field. The aims of this application are therefore:

1) To define the contribution of IL-17 versus IL-22 in H. hepaticus-induced colitis using anti-IL-17F and anti-IL-22 mAb as well as mice with a T cell specific deletion in gp130.

2) To functionally characterize the Th17 cells arising following H. hepaticus infection to establish the heterogeneity of this population in vivo.

3) To determine the kinetics of cecal versus colonic cytokine responses following H. hepaticus infection to elucidate the contribution of Th1 versus Th17 cells in intestinal inflammation at these two sites.

By characterizing H. hepaticus-induced Th17 responses and determining the role of these cells in disease pathogenesis, our studies will provide important new information concerning harmful immune responses to intestinal bacteria that will help in the design of strategies towards the treatment of chronic intestinal inflammation. Links fostered through the Hull York Medical School will ensure that results broadly applicable to chronic inflammation will be highlighted and opportunity for clinical research fully explored.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>427791</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Lymphocyte Signalling</gtr:department><gtr:description>Collaboration with Marc Veldhoen on the role of Tbet in Th17-cell phenotype switching</gtr:description><gtr:id>8A0CD71F-F0BD-4BD9-B328-040971D4D3C3</gtr:id><gtr:impact>Brucklacher-Waldert V, C Ferreira, S Innocentin, S Kamdar, DR Withers, MC Kullberg, and M Veldhoen. (2016) Tbet or continued ROR?t expression is not required for Th17-associated immunopathology. J. Immunol. 196: 4893-4904.</gtr:impact><gtr:outcomeId>58b5777b134ac8.45738786-1</gtr:outcomeId><gtr:partnerContribution>Transgenic mouse strains were generated at Babraham and were used by my research group in York to examine the role of Tbet in Th17-cell phenotype switching in the Helicobacter hepaticus colitis. Results from experiments performed in York were combined with data from collaborators lab (EAE model) and were submitted as a research paper to The Journal of Immunology. (Paper accepted in 2016.)</gtr:partnerContribution><gtr:piContribution>Transgenic mouse strains were generated at Babraham and were used by my research group in York to examine the role of Tbet in Th17-cell phenotype switching in the Helicobacter hepaticus colitis. Results from experiments performed in York were combined with data from collaborators lab (EAE model) and were submitted as a research paper to The Journal of Immunology. (Paper accepted in 2016.)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lay article in &quot;The Insider&quot; (2009 and 2010)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BF089FF0-628C-47EC-940A-AA59BD736603</gtr:id><gtr:impact>Wrote articles in lay language about ongoing research in the lab for &amp;quot;The Insider&amp;quot;, a newsletter produced by CICRA (Crohn's in Childhood Research Association).

Information for youngsters with inflammatory bowel disease and their families.</gtr:impact><gtr:outcomeId>8584B5E0621</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster at CICRA's Annual Meeting (2008)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84E7DFB1-2406-43E8-AF3C-363BCDF4642B</gtr:id><gtr:impact>Poster display at CICRA's Annual Meeting at the Institute of Child Health, London (June 7, 2008).

Information for youngsters with inflammatory bowel disease and their families.</gtr:impact><gtr:outcomeId>Fvj9QfvXWH6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop at CICRA's IBD Family Day (2009 and 2012)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A70376A3-9CE7-41F3-86C0-560045FD8ADD</gtr:id><gtr:impact>Participated in CICRA's Family Day for youngsters with IBD and their families in Edinburgh (3/10/09) and in Leeds (22/9/12). Co-chaired several small group discussion sessions on IBD research and answered questions on immunology from parents of children with IBD.

Information for youngsters with inflammatory bowel disease and their families.</gtr:impact><gtr:outcomeId>EBF1D832E9D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Hull York Medical School PhD studentship</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Hull York Medical School</gtr:fundingOrg><gtr:id>D82CDE39-085B-41E3-B699-960F1C48B689</gtr:id><gtr:outcomeId>SVttuUNkUti</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124173</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Industrial CASE PhD studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K501487/1 from BBSRC (~92K) + CASE contribution (~32K)</gtr:fundingRef><gtr:id>695D6145-CB68-4A20-8672-5E315DA0D2FE</gtr:id><gtr:outcomeId>gFdwmyKBUWe</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F4D07E1F-2B5C-43C3-B4D1-B4A9D5AF6505</gtr:id><gtr:title>Differential Requirements for IL-17A and IL-22 in Cecal versus Colonic Inflammation Induced by Helicobacter hepaticus.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99a284ba5f9aeffebb7c804091df8189"><gtr:id>99a284ba5f9aeffebb7c804091df8189</gtr:id><gtr:otherNames>Morrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>56dd9e9fa46b02.49460402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585A5816-1816-4B5F-A2FE-DF33E8B967E8</gtr:id><gtr:title>Tbet or Continued ROR?t Expression Is Not Required for Th17-Associated Immunopathology.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1398882300ad0ef51d4e16bee115325"><gtr:id>b1398882300ad0ef51d4e16bee115325</gtr:id><gtr:otherNames>Brucklacher-Waldert V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>585d66ce49ce21.25409575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF7D171-E7F4-46AF-A6D7-B619A1565892</gtr:id><gtr:title>Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99a284ba5f9aeffebb7c804091df8189"><gtr:id>99a284ba5f9aeffebb7c804091df8189</gtr:id><gtr:otherNames>Morrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>kTxQXfFCd23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ADBACD7-7A6D-4FE4-B5B6-42C817470F84</gtr:id><gtr:title>IL-23 and Th17 cytokines in intestinal homeostasis.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e42ce6fc0725bba02c774f132856049"><gtr:id>6e42ce6fc0725bba02c774f132856049</gtr:id><gtr:otherNames>Maloy KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>6FAB1AD82FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1F48819-2DA4-4208-8AA7-CC75CCF84787</gtr:id><gtr:title>Th17-cell plasticity in Helicobacter hepaticus-induced intestinal inflammation.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99a284ba5f9aeffebb7c804091df8189"><gtr:id>99a284ba5f9aeffebb7c804091df8189</gtr:id><gtr:otherNames>Morrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>LbvP2QPUnsi</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700806</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>